# Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT

> **NCT06861348** · PHASE2 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 23 (estimated)

## Conditions studied

- Leukemia, Lymphocytic, Acute

## Interventions

- **DRUG:** Inotuzumab Ozogamicin±Donor Lymphocyte Infusion

## Key facts

- **NCT ID:** NCT06861348
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06861348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06861348, "Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06861348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*